China's CanSino in talks for Covid vaccine Phase III trial overseas
July 11 2020 04:25 PM
International China
RELATED STORIES
Zhao Lijian

China orders some American media to give details on staff, after US move

Pro-China supporters celebrate with Hong Kong and Chinese flags after China's parliament passes nati

China passes national security law in turning point for Hong Kong

This file photo taken on September 11, 2019 shows a woman walking in an ethnic Uighur neighbourhood

China forcibly sterilises Uighurs: report

Riot police ask people to leave to avoid mass gathering during a silent protest against the looming

China to impose visa restrictions on US individuals over Hong Kong

People wear masks as they wait at an intersection in Beijing

China puts half a million people in lockdown as Beijing fights new cluster

Russia saudi arabia China Brazil Chile covid-19 vaccine CanSino Biologics
Co-Founder of CanSino Biologics Qiu Dongxu delivers a speech on the progress of company's coronaviru
Co-Founder of CanSino Biologics Qiu Dongxu delivers a speech on the progress of company's coronavirus vaccine candidate at the China Anti-viral Drug Innovation Summit, following the outbreak of the coronavirus disease, in Suzhou, Jiangsu province, China

Reuters/Suzhou/Beijing

Chinese vaccine developer CanSino Biologics is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental Covid-19 vaccine, its co-founder said on Saturday.
China's success in driving down Covid-19 infections has made it harder to conduct large-scale vaccine trials, and so far only a few countries have agreed to work with it.
"We are contacting and Russia, Brazil, Chile and Saudi Arabia (for the Phase III trial) and it's still in discussion," Qiu Dongxu, executive director and co-founder of CanSino, told an anti-viral drug development conference in Suzhou, in eastern China.
He said its Phase III trials were likely to start "pretty soon," and the company plans to recruit 40,000 participants for the tests.
Its Covid-19 candidate Ad5-nCov became the first in China to move into human testing in March but is running behind other potential vaccines in terms of trial progress. Two experimental vaccines developed by Sinovac Biotech and a unit of China National Pharmaceutical Group (Sinopharm) are already approved for Phase III trials.
Qiu said its Phase II trials involving 508 people have yielded "much better" results than Phase I about the vaccines safety and ability to trigger immune response. He did not disclose specific evidence.
He said its new factory under construction in China will allow it to produce 100-200 million doses of coronavirus vaccines per year by early 2021.
China's military, whose research unit is co-developing the vaccine candidate, approved its military use last month, while Sinopharm's two experimental shots are offered to employees at state-owned firms travelling overseas.
Zeng Guang, former chief epidemiologist at Chinese Center for Disease Control and Prevention, told the conference that Chinese construction groups overseas in particular are keen to take experimental vaccines.
He also said discussion should start whether to launch emergency inoculation of experimental vaccines "right now."
There are no approved vaccines yet for Covid-19, a respiratory disease caused by the new coronavirus, which has killed more than half a million people globally.



There are no comments.

LEAVE A COMMENT Your email address will not be published. Required fields are marked*
MORE NEWS

Top News

Persistently high food prices add more pressure to normalise interest rates: QNB date7/2/2022 5:51:41 PM
Qatar seen as global digital hub post-FIFA, says Microsoft official date7/1/2022 7:54:26 PM
QSE key index vaults 538 points; M-cap gains QR24bn date7/1/2022 7:49:49 PM

HAPPENING IN DOHAMore